Thailand Medical Device Regulator: MoPH, Thai FDA and MDCD Explained

1. Key takeaways

Medical devices in Thailand are regulated by the Thai Food and Drug Administration (Thai FDA, also written TFDA), which operates under the Ministry of Public Health (MoPH). Within the Thai FDA, the Medical Device Control Division (MDCD) is the operating unit that actually handles product registration, establishment licensing and post-market control. Reports of adverse events and field safety corrective actions (FSCA) are received by the Health Product Vigilance Centre (HPVC) set up under the Thai FDA. Understanding who does what among these three bodies is the first thing any market entrant should clarify, because every obligation in the Thai system can be traced back to one of them.

• The Ministry of Public Health sets the substantive rules: device classification, vigilance, labelling and GMP requirements are issued in the form of MoPH Notifications.
• The Thai FDA is the licensing and enforcement authority; its Secretary-General holds coercive powers such as ordering mandatory recalls.
• The MDCD is the working division: classification confirmation, dossier review, establishment licensing and post-licensing supervision all sit there.
• The governing law is the Medical Device Act B.E. 2551 (2008), as amended by the Medical Device Act (No. 2) B.E. 2562 (2019), which introduced the current four-class risk system and three registration pathways.
• Thailand is a member of the ASEAN Medical Device Directive (AMDD) and accepts dossiers in the ASEAN Common Submission Dossier Template (CSDT), but Thai national classification interpretations always prevail.
• The decisive structural point: only a Thai entity holding an Establishment Licence (Importer) may submit registrations, hold the certificate and import. Foreign manufacturers cannot hold a Thai registration directly.

2. Legal basis

The superior law is the Medical Device Act B.E. 2551 (2008). The Medical Device Act (No. 2) B.E. 2562 (2019) then introduced the current risk-based classification and the three registration pathways, supported by detailed MoPH Notifications. One point deserves special attention because it is among the most frequent misreadings found in second-language summaries of Thai regulation: Thai device legislation is dated exclusively in the Buddhist Era (B.E.) calendar, and the conversion is simply B.E. minus 543 equals the Gregorian year. On that basis, B.E. 2551 corresponds to 2008, B.E. 2562 to 2019, B.E. 2563 to 2020, B.E. 2566 to 2023, B.E. 2568 to 2025 and B.E. 2569 to 2026. Anyone who reads a Thai notification without performing this conversion risks treating an instrument that is already in force as a distant future proposal, which in practice leads to systematic underestimation of regulatory urgency. A short reference table makes the conversion unambiguous: B.E. 2551 equals 2008, B.E. 2562 equals 2019, B.E. 2563 equals 2020, B.E. 2566 equals 2023, B.E. 2568 equals 2025 and B.E. 2569 equals 2026.

As for the ASEAN dimension, Thailand is a member of the ASEAN Medical Device Directive, adopts the ASEAN CSDT as the technical dossier format, and aligns its classification rules with the AMDD framework. However, Thailand maintains its own national interpretive rules for classification, and a classification level assigned in another jurisdiction, whether in the European Union or the United States, can never substitute for the Thai determination. The Thai class must always be established against the Thai notification.

3. Expert insights

The single most important concept for a foreign, and especially a Chinese, manufacturer entering Thailand is that the licence holder is the true watershed of this market. Thai law requires that only a Thai entity duly established in Thailand and holding an Establishment Licence (Importer) may submit a product registration, hold the registration certificate and clear goods through import. A foreign manufacturer cannot hold a Thai registration certificate in its own name. Moreover, as a matter of practical estimate in the market, the licence holder, the importer of record and the authorised representative must be one and the same legal entity. This differs fundamentally from the European model, where the authorised representative is designed as an independent role separate from distribution. When assessing a prospective Thai partner, a practical estimate of its real execution capability rests on three things: a valid Establishment Licence (Importer) in force; office and warehouse premises that have passed the Thai FDA on-site inspection; and registration certificates actually held in its own name that can be verified in official records. All three must be present; a business licence and a glossy brochure are nowhere near sufficient.

4. Practical recommendations

• Map every Thai obligation to the correct authority before drafting any plan: MoPH Notifications for substantive rules, the Thai FDA for licences and enforcement, the MDCD for filings and review, and the HPVC for adverse event and FSCA reporting.
• Convert every B.E. date at the moment you record it, writing the Gregorian year alongside, so that no colleague ever mistakes B.E. 2569 (2026) for a distant future instrument.
• Treat the AMDD alignment as a format convenience only; always re-derive the Thai classification under the Thai notification rather than importing an EU or US class.
• Structure the market entry around a Thai licence-holding entity from day one, and confirm early that the licence holder, importer of record and authorised representative roles will sit in the same legal entity.
• When qualifying a Thai partner, verify the Establishment Licence (Importer), the on-site inspection record and the certificates actually held, and record the evidence in writing.

5. Verification checklist

• □ Medical Device Act B.E. 2551 (2008) confirmed as the superior law (pending verification against the Royal Gazette text).
• □ Medical Device Act (No. 2) B.E. 2562 (2019) amendments confirmed (pending verification).
• □ Thai FDA English website en.fda.moph.go.th, For Commercial Purpose process description, Steps 3 to 7 (pending verification).
• □ MoPH medical device risk classification notification B.E. 2562, published in the Government Gazette on 18 December 2019 (pending verification).
• □ Thai FDA adverse event and FSCA guidance issued through the Health Product Vigilance Centre (HPVC) (pending verification).

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Thailand. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with the Thai FDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com